Loading company
Tenon Medical, Inc.
TNON · Nasdaq · ·
$2.72-5.1%Sep 29 close
- 1M
- -45.7%
- 6M
- -88.5%
- 1Y
- -93.4%
TNON · Nasdaq · ·
$2.72-5.1%Sep 29 close
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $1.3M | $564K | +126.77% |
| Profit | -$4.1M | -$2.8M | -46.26% |
| Profit per share | -$0.22 | -$7.71 | +97.15% |
| Free Cash Flow | -$2.9M | -$2.7M | -6.93% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Tenon Medical, Inc. has no earnings call transcript available.
Releases land after the close or before the open, so the move is the session that follows.
Tenon Medical, Inc. is a medical device company dedicated to transforming care for patients with certain sacro-pelvic disorders. Tenon was incorporated in the State of Delaware in 2012 and currently offers two systems to treat a diseased sacroiliac joint (the "SI Joint"). The Company has developed The Catamaran® SI Joint Fusion System that offers a novel, less invasive approach to the SI Joint using a single, robust titanium implant. In August 2025, the Company acquired substantially all the assets of SiVantage, Inc. and SIMPL Medical, LLC, including the SImmetry+® SI Joint Fusion System, which treats disorders of the SI Joint through a minimally invasive lateral access solution that incorporates well-established orthopedic fusion principles. Since the national launch of The Catamaran System in October 2022, Tenon is focused on three commercial opportunities: 1) primary SI Joint procedures, 2) revision procedures of failed SI Joint implants and 3) SI-Joint fusion adjunct to a spine fusion construct. 3
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Tenon Medical, Inc.’s Item 2.02 8-K filed August 13, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.